These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 7908263)
1. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263 [TBL] [Abstract][Full Text] [Related]
2. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126 [TBL] [Abstract][Full Text] [Related]
3. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947 [TBL] [Abstract][Full Text] [Related]
4. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
5. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Dolzan V; Rudolf Z; Breskvar K Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185 [TBL] [Abstract][Full Text] [Related]
6. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046 [TBL] [Abstract][Full Text] [Related]
7. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Roots I; Brockmöller J; Drakoulis N; Loddenkemper R Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678 [TBL] [Abstract][Full Text] [Related]
8. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816 [TBL] [Abstract][Full Text] [Related]
9. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Hirvonen A; Husgafvel-Pursiainen K; Karjalainen A; Anttila S; Vainio H Cancer Epidemiol Biomarkers Prev; 1992; 1(6):485-9. PubMed ID: 1284589 [TBL] [Abstract][Full Text] [Related]
10. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility]. Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353 [TBL] [Abstract][Full Text] [Related]
11. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Sobti RC; Sharma S; Joshi A; Jindal SK; Janmeja A Biomarkers; 2003; 8(5):415-28. PubMed ID: 14602525 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940 [TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Xu X; Kelsey KT; Wiencke JK; Wain JC; Christiani DC Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):687-92. PubMed ID: 8877059 [TBL] [Abstract][Full Text] [Related]
14. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153 [TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Nakachi K; Imai K; Hayashi S; Kawajiri K Cancer Res; 1993 Jul; 53(13):2994-9. PubMed ID: 8319207 [TBL] [Abstract][Full Text] [Related]
16. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Kawajiri K; Eguchi H; Nakachi K; Sekiya T; Yamamoto M Cancer Res; 1996 Jan; 56(1):72-6. PubMed ID: 8548778 [TBL] [Abstract][Full Text] [Related]
17. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Skoda RC; Gonzalez FJ; Demierre A; Meyer UA Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325 [TBL] [Abstract][Full Text] [Related]
18. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Goto I; Yoneda S; Yamamoto M; Kawajiri K Cancer Res; 1996 Aug; 56(16):3725-30. PubMed ID: 8706015 [TBL] [Abstract][Full Text] [Related]
20. CYP1A1 gene polymorphisms and smoking status as modifier factors for lung cancer risk. Hussein AG; Pasha HF; El-Shahat HM; Gad DM; Toam MM Gene; 2014 May; 541(1):26-30. PubMed ID: 24613751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]